👋 Hey, let’s get into it. The American Diabetes Association's annual meeting took over New Orleans this past weekend, bringing together thousands of researchers, physicians, and drug developers to discuss the future of diabetes care.

But ADA's most talked about story wasn't a drug…

A University of Washington diabetes researcher was escorted out of the conference by police after distributing copies of an editorial criticizing federal research funding cuts. The researcher later returned and continued handing out the paper before being warned he could be arrested if he reentered the convention center. Not exactly the type of update attendees expected between poster sessions. 😂

Meanwhile, the conference's biggest scientific stories weren't really about diabetes at all. Weight loss drugs dominated the conversation, and we break down the most important ADA takeaways in today's Deep Dive.

🦾 Alnylam Commits Up to $2B to AI Pioneer Inceptive for Next-Gen RNAi Design
Alnylam is betting that the future of RNAi drug discovery looks a lot like the future of artificial intelligence. The company agreed to pay $30 million upfront and up to $2 billion in milestones to partner with Inceptive, a startup co-founded by Jakob Uszkoreit, one of the researchers behind the Transformer architecture that helped enable modern AI models. After exploratory work showed Inceptive's platform could rapidly adapt to siRNA programs and generate meaningful biological insights from relatively small datasets, Alnylam decided to go all in. The collaboration aims to improve target modeling, sequence optimization, and chemical modification design for future RNAi therapeutics. AI continues its march from software into the core of drug development.

🩸 Incyte Pays $1.25B Upfront for Vega Therapeutics' Bleeding Disorder Drug
Incyte just made the largest acquisition of Bill Meury's tenure as CEO, agreeing to pay $1.25 billion upfront and up to $750 million in milestones for Vega Therapeutics, a subsidiary of Star Therapeutics. The centerpiece is VGA039, a phase 3 antibody for von Willebrand disease that reduced bleeding rates by as much as 81% in early studies and can be administered once every four weeks. The deal helps Incyte prepare for life after Jakafi's patent expiration in 2028 while positioning the company to compete with Takeda's Vonvendi. Management believes the program could eventually generate more than $1 billion in annual sales.

💰 J&J Drops $1B to Acquire Firefly Bio's Degrader Antibody Conjugate Platform
Johnson & Johnson is making an early move into one of oncology's hottest emerging modalities. The company agreed to pay $1 billion upfront for Firefly Bio and its degrader antibody conjugate (DAC) platform, which combines targeted protein degraders with antibody-drug conjugate technology. Instead of delivering traditional chemotherapy payloads, DACs deliver protein degraders capable of eliminating disease-driving targets, including some considered "undruggable." Firefly's lead efforts focus on KRAS-driven cancers, and preclinical studies have shown meaningful tumor reductions at relatively low doses. ADCs are already reshaping oncology. J&J is betting DACs could be the next evolution.

💵 Roche Wagers up to $2.3B on Nurix's BTK Degrader to Challenge Lilly
Roche is paying $700 million upfront and committing up to $2.3 billion in milestones to co-develop Nurix's BTK degrader bexobrutideg. The molecule is headed toward a phase 3 showdown with Eli Lilly's Jaypirca and represents one of the most advanced examples of targeted protein degradation in hematology. Nurix believes removing BTK entirely, rather than simply inhibiting it, could produce better outcomes for patients with blood cancers. Early clinical data have been encouraging, with progression-free survival appearing stronger than results reported for Jaypirca, though cross-trial comparisons come with obvious caveats. Roche clearly sees enough potential to place a multibillion-dollar wager.

🤯 Tango and Revolution Medicines Post 92% Response Rate in Pancreatic Cancer Study
Few diseases humble drug developers quite like pancreatic cancer, which is why investors reacted so strongly to new data from Tango Therapeutics and Revolution Medicines. In a small cohort of 12 patients, the combination of Tango's PRMT5 inhibitor vopimetostat and Revolution's RAS inhibitor achieved a remarkable 92% response rate and 100% disease control rate. The results exceeded what either company had previously demonstrated individually and prompted analysts to describe the findings as "unprecedented." Investors responded immediately, sending Tango shares soaring 43% in a single day. If larger studies confirm these findings, this could become one of the most closely watched pancreatic cancer programs in biotech.

💻 100+ ChatGPT Prompts to Revolutionize Your Day
Discover how you can leverage ChatGPT to boost efficiency, streamline tasks, and stay ahead in your industry. Supercharge your productivity with HubSpot's comprehensive guide.

🚪 Medicare Opens the Door to Low-Cost GLP-1 Access for Millions of Seniors
Starting July 1, millions of Medicare beneficiaries can access obesity GLP-1 therapies for roughly $50 per month, setting up a new Lilly-versus-Novo battle.

🏛️ New House Bill Targets U.S.-China Biotech Deals
Lawmakers introduced legislation that could require government review of biotech licensing deals and investments involving Chinese companies.

😬 Takeda Records $2.5B Legal Charge After Landmark Antitrust Verdict
An $885 million jury verdict tied to Amitiza could ultimately exceed $2.5 billion, pushing Takeda from profit to loss.

📉 ADC Therapeutics Shares Crash 52% After Excess Deaths in Phase 3 Trial
Twenty-seven deaths in the treatment arm versus nine in control raised fresh concerns about the safety profile of Zynlonta.

🎟️ FDA Voucher Program Faces Transparency Criticism at First Public Hearing
Industry groups largely backed the CNPV program, while physicians and policy experts called for greater transparency and a temporary pause.

🏆 Innovent Scores Phase 3 Victory in Gastric Cancer
Innovent's Takeda-partnered gastric cancer ADC met its primary endpoint, strengthening Takeda's position in the race for next-generation CLDN18.2 therapies.

Hosting the American Diabetes Association (ADA) conference in New Orleans feels borderline cruel. You spend all day discussing obesity drugs and blood sugar control, then spend the evening surrounded by gumbo, po'boys, and enough beignets to make your Fitbit file a formal complaint. Unsurprisingly, the meeting's biggest stories weren't really about diabetes. With obesity drug sales projected to bring in $200B annually by 2027, ADA increasingly resembles the annual summit of weight-loss.

Here are the top stories from the conference:

🏆 Lilly's Retatrutide Keeps Looking Best-in-Class
Eli Lilly spent ADA showing why competitors are paying close attention to retatrutide. Patients achieved more than 30% average weight loss after extended treatment, numbers that start creeping into bariatric surgery territory. The drug also improved sleep apnea, osteoarthritis pain, cholesterol, blood pressure, and blood sugar control. Lilly is increasingly becoming a company building an obesity portfolio rather than a single obesity drug, with management projecting as many as five approved obesity medicines by the end of the decade.

📉 Zealand Shares Sink 23% as Obesity Drug's Dropout Rate Raises Concerns
Zealand Pharma investors got an unpleasant surprise Monday morning after new ADA data highlighted a potential weakness in survodutide, the obesity drug the company licensed to Boehringer Ingelheim. While the phase 3 study confirmed meaningful weight loss and impressive reductions in visceral fat and liver fat, nearly 19% of patients discontinued treatment due to gastrointestinal side effects, far above rates reported for Lilly's Zepbound and Novo's Wegovy. The tolerability concerns overshadowed the efficacy results and sent Zealand shares tumbling. The setback doesn't derail the program, but it reinforces a growing reality in obesity: weight loss alone may no longer be enough if patients struggle to stay on treatment.

📅 Pfizer Bets Patients Want Monthly Weight Loss Shots
Pfizer used ADA to strengthen the case for berobenatide, the obesity asset it acquired through its $10 billion Metsera deal. New data showed nearly 16% weight loss without evidence of plateauing, while the company continues pushing toward monthly dosing schedules. If efficacy remains competitive, reducing injections from weekly to monthly could become a meaningful convenience advantage. Pfizer is now planning ten late-stage studies, making clear it intends to be a major obesity player.

❤️ Amgen Reminds Everyone That Cardiovascular Disease Still Matters
While competitors battled over weight-loss percentages, Amgen highlighted new Repatha data showing a 29% reduction in major cardiovascular events among high-risk diabetes patients. The company also continued building anticipation around MariTide, its long-acting obesity candidate that may eventually be administered every two months or even quarterly. As obesity treatment evolves, the winners may be the companies that improve both waistlines and long-term health outcomes.

🐢 Roche and Zealand Make the Case for "Gentler" Weight Loss
Not every obesity drug needs to win on maximum pounds lost. Roche and Zealand highlighted petrelintide's relatively mild side-effect profile, with only 1.5% of patients discontinuing due to gastrointestinal issues. Weight loss reached 10.7%, below what leading GLP-1 therapies achieve, but supporters argue many patients may prioritize tolerability over squeezing out every last percentage point of weight reduction. In a market expected to support multiple winners, that argument may prove surprisingly important.

Novo Nordisk's Wegovy pill has officially surpassed three million prescriptions in just over five months, making it one of the strongest pharmaceutical launches by volume in U.S. history. That's roughly one prescription filled every five seconds. Even more notable, most prescriptions came from patients who had never previously used a GLP-1 therapy, suggesting the obesity market may be expanding far faster than many expected.

Here’s what biotech Redditors are talking about:

🤖 Are Autonomous Labs the Future or Just the Latest Buzzword?
A Reddit thread about Ginkgo’s automation push quickly turned into a broader debate about AI, robotics, and the future of wet-lab science. Most commenters landed in the same place: repetitive, predictable workflows are increasingly fair game for automation, but experimental design, troubleshooting, and real-world decision-making remain stubbornly human problems. One commenter summed it up neatly: automated labs will likely expand, but scientists who can adapt alongside the technology will stay in demand.

🙌 Biotech Recruiter Says Hiring Is Back, But It Looks Different Now
A life sciences executive search partner jumped onto r/biotech for an AMA, and the timing couldn't have been better. His view: the market is materially healthier than it was a few years ago thanks to strong M&A activity and renewed investor deployment. The catch? Biotechs are running leaner than ever, favoring smaller teams, fractional experts, and development-focused hiring over the massive research organizations that defined the last funding cycle. In other words, opportunities are improving, but the days of building a 50-person discovery team before generating clinical data may be over.

📉 Massachusetts Life Sciences Jobs Slip for the First Time Since 2010
Industry employment fell 1% in 2025, ending a 14-year growth streak, though projections still forecast nearly 10% growth by 2030.

⚖️ SCOTUS Delivers a Major Win for Generic Drugmakers
The Supreme Court unanimously backed Hikma in its Vascepa dispute with Amarin, reinforcing the industry's use of "skinny label" strategies. Skinny label…big win.

🪓 Fulcrum Cuts 85% of Staff After Lead Program Collapse
The biotech will shrink from 57 employees to just 9 as it explores strategic alternatives following its sickle cell setback.

💊 FDA Launches New Review of Abortion Pill Safety Data
The investigation into mifepristone could shape future regulatory restrictions despite decades of FDA safety findings.

💻 Scispot Raises $8M to Build the Operating System for Modern Labs
If you've ever peeked behind the curtain of a biotech lab, you know the reality is less "cutting-edge science" and more "where did that spreadsheet go?" Data lives in one system, instruments in another, and critical approvals often bounce around inboxes like a game of hot potato. Scispot wants to clean up the chaos. Its platform stitches together instruments, workflows, audit trails, approvals, and sample tracking into a single system built for regulated labs. The startup says it's now used by more than 100 labs, connects with 250+ instrument types, and manages millions of samples as it chases a bigger goal: helping labs run less like a patchwork of software and more like a modern operating system.

🧠 June 9, 1875 — The Father of Chemical Neurotransmission Is Born
Before neurotransmitters were a thing, scientists were still arguing over a basic question: how do nerves actually talk to each other? Enter Sir Henry Dale. Born on this day, Dale isolated acetylcholine and helped prove that nerves communicate using chemicals, not just electrical signals, settling one of biology's biggest scientific beefs. The breakthrough earned him a Nobel Prize and laid the groundwork for everything from Alzheimer's drugs to modern anesthesia. The next time your coworker does something that strikes a nerve, pour one out for Sir Henry Dale.

Imagine spending all day listening to presentations about losing 20% of your body weight and then walking outside into a city where someone is actively frying dough and covering it in powdered sugar.

ADA picked New Orleans and said, "We're going to test your commitment to lifestyle modification."

That’s all for today. See you Thursday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.